| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 11, 2006
Accepted on May 14, 2007
From the II. Medizinische Klinik (P.W., M.O., M.C., U.H., H.M., T.M., A.D.), Johannes-Gutenberg-Universität Mainz, Germany; Institut für Pharmakologie (M.H., H.L., U.F.), Johannes-Gutenberg-Universität Mainz, Germany; Institut für Pharmazie (A.S., J.L.), Friedrich-Schiller-Universität Jena, Germany; Actavis Deutschland GmbH (D.S.), Langenfeld, Germany; and the Department of Biochemistry (H.W.), Purdue University, West Lafayette, Ind.
* To whom correspondence should be addressed. E-mail: tmuenzel{at}uni-mainz.de.
Objective--Nitrate tolerance is likely attributable to an increased production of reactive oxygen species (ROS) leading to an inhibition of the mitochondrial aldehyde dehydrogenase (ALDH-2), representing the nitroglycerin (GTN) and pentaerythrityl tetranitrate (PETN) bioactivating enzyme, and to impaired nitric oxide bioactivity and signaling. We tested whether differences in their capacity to induce heme oxygenase-1 (HO-1) might explain why PETN and not GTN therapy is devoid of nitrate and cross-tolerance.
Methods and Results--Wistar rats were treated with PETN or GTN (10.5 or 6.6 µg/kg/min for 4 days). In contrast to GTN, PETN did not induce nitrate tolerance or cross-tolerance as assessed by isometric tension recordings in isolated aortic rings. Vascular protein and mRNA expression of HO-1 and ferritin were increased in response to PETN but not GTN. In contrast to GTN therapy, NO signaling, ROS formation, and the activity of ALDH-2 (as assessed by an high-performance liquid chromatography-based method) were not significantly influenced by PETN. Inhibition of HO-1 expression by apigenin induced "tolerance" to PETN whereas HO-1 gene induction by hemin prevented tolerance in GTN treated rats.
Conclusions--HO-1 expression and activity appear to play a key role in the development of nitrate tolerance and might represent an intrinsic antioxidative mechanism of therapeutic interest.
Related Article:
This article has been cited by other articles:
![]() |
A. Pautz, P. Rauschkolb, N. Schmidt, J. Art, M. Oelze, P. Wenzel, U. Forstermann, A. Daiber, and H. Kleinert Effects of nitroglycerin or pentaerithrityl tetranitrate treatment on the gene expression in rat hearts: evidence for cardiotoxic and cardioprotective effects Physiol Genomics, July 9, 2009; 38(2): 176 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Wenzel, E. Schulz, T. Gori, M. A. Ostad, F. Mathner, S. Schildknecht, S. Gobel, M. Oelze, D. Stalleicken, A. Warnholtz, et al. Monitoring White Blood Cell Mitochondrial Aldehyde Dehydrogenase Activity: Implications for Nitrate Therapy in Humans J. Pharmacol. Exp. Ther., July 1, 2009; 330(1): 63 - 71. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Hink, A. Daiber, N. Kayhan, J. Trischler, C. Kraatz, M. Oelze, H. Mollnau, P. Wenzel, C. F. Vahl, K. K. Ho, et al. Oxidative Inhibition of the Mitochondrial Aldehyde Dehydrogenase Promotes Nitroglycerin Tolerance in Human Blood Vessels J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2226 - 2232. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Gutterman Combating Nitrate Tolerance: A Novel Endogenous Mechanism Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1673 - 1676. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |